ClinicalTrials.gg
RecruitingNCT04783857Updated Jul 13, 2026

Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children

A Phase 4 interventional study of Progesterone 200 MG Oral Capsule in Smoking, Smoking Cessation and Smoking Reduction, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Primary conditionSmoking ReductionRegistry: SmokingReclassifiedWhy we changed it
Registry
Smoking — the first condition term the registry derived for this study.
ClinicalTrials.gg
Smoking Reduction
Why
  1. The study's listed conditions name Smoking Reduction, a narrower term within Smoking.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Minnesota · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 6 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
171
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The investigators aim to address the following specific aims:

  • Determine the efficacy of Prog in preventing postpartum smoking relapse and reducing smoking relapse risk factors.
  • Examine the effects of this maternal smoking intervention on infant health.
  • Examine racial and ethnic differences in intervention outcomes.
Read the detailed description

This Good Clinical Practice clinical trial will be implemented by an experienced, transdisciplinary, and productive team of investigators to enhance the diversity of the study sample and generalizability of results. We will enroll healthy pregnant women (following enrollment, all subsequent study procedures will be completed postpartum) or postpartum women on hormonal birth control or no hormonal birth control with either a recent history of smoking and a desire to remain abstinent after childbirth, or who are currently smoking and motivated to quit smoking. Participants will be recruited throughout the continental United States (US) and will participant in an observational arm of the study. Participants living in Minnesota (our clinical site) will receive a 12-week course of exogenous progesterone. All participants will be followed for six months with remote visits, self-administered surveys, and self-collection of dried blood spots to measure hormones and smoking-related biomarkers.

02

Conditions studied

  • Smoking
  • Smoking Cessation
  • Smoking Reduction

Browse trials for

03

In context

Smoking Reduction Reclassified

56 studies on the registry are indexed under Smoking Reduction; 13 are open to participants now.

This study's planned enrollment of 171 is below the median of 222 across 48 interventional studies indexed under Smoking Reduction.

Browse Smoking Reduction studies →

Lead sponsor

University of Minnesota is the lead sponsor of 1,216 studies on the registry; 197 are open to participants now.

Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.

Compared within Smoking Reduction, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Smoking. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide ,
  • Aged 18 to 45 years old
  • Self-reported stable physical and mental health

    1. self-report uncomplicated pregnancy at gestational week 30 or beyond, or
    2. self-report the birth of a child within the past 6 months
  • History of ≥ 4 cigarettes per month during the six months prior to pregnancy
  • At enrollment, self-report of motivation to become and/or remain abstinent after delivery ≥ 6 on a 10 point Likert-type scale
  • Willingness to protect against pregnancy following day 0 to week 12 of the study
  • Participants must live in the continental US and have a device to fully participate in the protocol

Exclusion criteria

Exclusion Criteria:

  • Current daily use of nicotine replacement therapy or smoking cessation medications, with the exception of e-cigarettes
  • Current major depressive disorder based on the Patient Health Questionnaire-9 (PHQ-9) and the Beck Depression Inventory
  • to progesterone treatment (e.g., current use of drugs that may inhibit ; current or history of deep vein thrombosis, pulmonary embolus, clotting or bleeding disorder, hypertension, stroke, heart disease, or liver dysfunction or disease; or peanut allergy),
  • Current or within the past 3 months treatment for illicit drug use or alcohol use
  • Any condition or issue that, in the opinion of the clinical team, precludes participation in the trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
171 participants (estimated)

Study arms

  • Active comparator
    Group 1

    Participants in this group will receive progesterone

    Drug: Progesterone 200 MG Oral Capsule

  • No intervention
    Group 2

    Participants in this group will not receive progesterone

Interventions

06

What researchers measure

Primary outcomes

  1. Smoking abstinence at Month 6

    Time frame: 6 months

  2. Child health assessed as smoke exposure and acute infant health.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Abdelwahab N, Allen A, Harrison K, Petersen A, Allen S. A protocol for modifying progesterone to increase postpartum cigarette smoking abstinence and reduce secondhand smoke exposure in infants. Contemp Clin Trials Commun. 2024 Nov 6;42:101389. doi: 10.1016/j.conctc.2024.101389. eCollection 2024 Dec. PubMed 39618477 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Jun 2027, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2021
First posted
Mar 5, 2021
StartActual
Apr 14, 2022
Primary completionEst.
Jun 2, 2027
CompletionEst.
Jun 2, 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04783857
Responsible party
Sponsor
First posted
Mar 5, 2021
Start date
Apr 14, 2022
Primary completion
Jun 2, 2027 (estimated)
Completion
Jun 2, 2027 (estimated)
Last update
Jul 13, 2026

Study contacts

Katherine Harrison, MPH
Contact
harr0644@umn.edu
612-624-5377
Sharon Allen, MD, PhD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Progesterone

Start the discussion